Drug Trial Radar · NCT03818035
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
880
Actual
Start
Feb 8, 2019
Primary completion
Mar 7, 2022
Study completion Jan 7, 2025
Sponsor
- Lead sponsor
- Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks).
Conditions
- Psoriasis
Interventions
GuselkumabDrug
Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
Placebo InjectionDrug
Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68Time frame: Week 68
Locations
90 sites in 2 countries. Site status is shown where the registry gives one.
Hopital Prive d'Antony
Antony, France
Centre Hospitalier d'Auxerre
Auxerre, France
Polyclinique Reims Bezanne - De Courlancy
Bezanne, France
Centre Hospitalier Le Mans
Le Mans, France
Hôpital Edouard Herriot
Lyon, France
Le Bateau Blanc
Martigues, France
CHU Nantes
Nantes, France
CHU de Nice Hopital de l Archet
Nice, France
CHU Rouen
Rouen, France
HIA se Sainte-Anne - Toulon
Toulon, France
CHU Toulouse
Toulouse, France
Universitätsklinikum Aachen
Aachen, Germany
DermaManagement Augsburg GmbH
Augsburg, Germany
Klinikum Augsburg
Augsburg, Germany
Fachklinik Bad Bentheim
Bad Bentheim, Germany
Hautmedizin Bad Soden
Bad Soden am Taunus, Germany
Charite CCM, Dermatologie
Berlin, Germany
Vivantes Klinikum Im Friedrichshain
Berlin, Germany
Rothhaar Studien GmbH
Berlin, Germany
ISA - Interdisciplinary Study Association GmbH
Berlin, Germany
Hautarztpraxis
Berlin, Germany
Hautarztpraxis Dr.Wildfeuer
Berlin, Germany
Hautarztpraxis
Berlin, Germany
Praxis 'Haut Pur'
Berlin, Germany
Klinikum Bielefeld Rosenhoehe
Bielefeld, Germany
Katholisches Klinikum Bochum gGmbH
Bochum, Germany
Niesmann & Othlinghaus GbR
Bochum, Germany
MVZ Dermatologisches Zentrum Bonn GmbH
Bonn, Germany
Universitatsklinikum Bonn
Bonn, Germany
Hautarztpraxis
Borna, Germany
Hautarztpraxis
Bramsche, Germany
Derma Nord
Bremen, Germany
Universitaetsklinikum Koeln
Cologne, Germany
Klinikum Darmstadt GmbH - Hautklinik
Darmstadt, Germany
Rosenpark Research GmbH
Darmstadt, Germany
Klinische Forschung Dresden GmbH
Dresden, Germany
Praxis für Dermatologie und Venerologie
Dresden, Germany
University Hospital Dresden
Dresden, Germany
Pro Derma
Dülmen, Germany
Privatpraxis Dr. Hilton & Partner
Düsseldorf, Germany
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.